Thank you for registering with Pulmonary Fibrosis New’s Clinical Trial Registry.
We will inform you of new clinical trials as information becomes available.
In the meantime, feel free to access these other PF-related resources:
Ofev News:
- Study Links Esbriet, Ofev to Significant Gastrointestinal Side Effects
- Bionews’ PF Forum Offers Patients, Caregivers a Space for Learning, Support
- Ofev-Sildenafil Combo May Improve Heart Health in IPF Patients with Right Heart Dysfunction, Study Suggests
- Algernon’s Investigational Anti-fibrotic, NP-120, Surpasses Esbriet, Ofev in Reducing Scarred Tissue in IPF Mice
- Ofev Benefits IPF Patients Irrespective of Initial Prognosis, Trials’ Data Show
- Despite Benefits, Many IPF Patients Switching from Esbriet to Ofev Stop Treatment, Possibly Due to Low BMI, Study Says
- IPF Patients Live Longer on Ofev Compared with Placebo, Analysis Suggests
IPF News:
- FDA Grants Orphan Drug Status to Nitric Oxide as Potential IPF Treatment
- How I Prepared for ‘the Call’ as a Caregiver
- FDA Approves Phase 2 Trial of Potential IPF Therapy GKT831
- Genetic Variants of MUC5AC Gene May Be a Risk Factor for IPF, Study Suggests
- Repeated Lung Cancer Surgery in IPF Patients May Worsen Outcomes
- Online ‘Personal Health’ Campaign Aims to Educate and Empower People with Lung Diseases
- Breathing Easier on the Canadian West Coast
Esbriet News:
- Real-world Esbriet Results Are Comparable to Those of Clinical Trials, Study Says
- Study Links Esbriet, Ofev to Significant Gastrointestinal Side Effects
- Bionews’ PF Forum Offers Patients, Caregivers a Space for Learning, Support
- Taking Esbriet for IPF Does Not Increase Risk of Heart Problems, Analysis Says
- IPF Patients Older Than 75 More Likely to Stop Taking Esbriet Because of Adverse Reactions, Japanese Study Suggests
- IPF Patients in Spain, Other Countries Share Similar Characteristics to Allow Comparison and Pooling, Study Suggests
- Algernon’s Investigational Anti-fibrotic, NP-120, Surpasses Esbriet, Ofev in Reducing Scarred Tissue in IPF Mice
CPF News:
- Evel Knievel: Dedicated to Defying Death, Lost To IPF
- PFF Brings Daughters of PF Program Under Its Wings
- CPF Names 2014 Most Important Year for Pulmonary Fibrosis
- FDA Includes CPF Advocates in IPF Workshop
- CPF Organizing a Series of Educational Activities for the 2014 Pulmonary Fibrosis Awareness Month
- PFF and CPF Documentary About Idiopathic Pulmonary Fibrosis to Air on Discovery Channel
- Coalition for Pulmonary Fibrosis Group Leads National Pulmonary Fibrosis Month
IPF Clinical Trial News:
- 4 Factors that Impact Pulmonary Fibrosis Prevention
- Galecto’s Inhaled TD139 a Promising Therapy for IPF, Scottish Study Finds
- Bellerophon’s INOpulse Inhaled Nitrous Oxide Device Improves Symptoms of PH-IPF Patients, Study Finds
- Kadmon Presents Preclinical Data Supporting ROCK Inhibition as Way of Treating PF
- First Patient Enrolled in Trial of Ofev for Progressive Fibrosing Interstitial Lung Disease
- IPF Patients on Esbriet Live Approximately 2.5 Years Longer Than Untreated Patients, Study Finds
- Clinical Trial Shows TD139 as a Promising Therapy Against Pulmonary Fibrosis, Maker Says
FDA News:
- FDA Grants Orphan Drug Status to Nitric Oxide as Potential IPF Treatment
- EmphyCorp’s N115 Completes Phase 3 Trial for FDA Marketing Application in PF Patients
- FDA Approves Phase 2 Trial of Potential IPF Therapy GKT831
- Plans for Phase 2 Trial of Brilaroxazine in IPF Patients Moving Ahead, Reviva Says
- PRM-151 Receives FDA Breakthrough Therapy Designation for IPF Treatment
- Saracatinib, Potential Oral IPF Therapy, Granted Orphan Drug Status by FDA
- FDA Clears Way for First Trials of IPF Treatment Candidate X-165